Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Investigator Sponsored Phase I Trial of Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

Trial Profile

An Investigator Sponsored Phase I Trial of Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2018

At a glance

  • Drugs Cytarabine (Primary) ; Cytarabine (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Idarubicin (Primary) ; Selinexor (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms FLAGINEXOR
  • Most Recent Events

    • 17 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top